Richard Sloan from the University of Michigan was first to document what is referred to as the "accrual anomaly". His 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Bora Pharmaceuticals Co's Sloan Ratio %
For the Drug Manufacturers - Specialty & Generic subindustry, Bora Pharmaceuticals Co's Sloan Ratio %, along with its competitors' market caps and Sloan Ratio % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bora Pharmaceuticals Co's Sloan Ratio % Distribution in the Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Bora Pharmaceuticals Co's Sloan Ratio % distribution charts can be found below:
* The bar in red indicates where Bora Pharmaceuticals Co's Sloan Ratio % falls into.
Bora Pharmaceuticals Co Sloan Ratio % Calculation
Earnings contain a lot of non cash earnings which is called accruals. The Sloan ratio is a way to identify firms with low non-cash or accrual-derived earnings relative to their cash flow.
Bora Pharmaceuticals Co's Sloan Ratio for the fiscal year that ended in Dec. 2023 is calculated as
Bora Pharmaceuticals Co's Net Income for the trailing twelve months (TTM) ended in Sep. 2024 was 565.607 (Dec. 2023 ) + 716.137 (Mar. 2024 ) + 1171.815 (Jun. 2024 ) + 1446.603 (Sep. 2024 ) = NT$3,900 Mil.
Bora Pharmaceuticals Co's Cash Flow from Operations for the trailing twelve months (TTM) ended in Sep. 2024 was 1155.554 (Dec. 2023 ) + 1236.798 (Mar. 2024 ) + -2095.427 (Jun. 2024 ) + 2068.798 (Sep. 2024 ) = NT$2,366 Mil.
Bora Pharmaceuticals Co's Cash Flow from Investing for the trailing twelve months (TTM) ended in Sep. 2024 was 36.769 (Dec. 2023 ) + -480.702 (Mar. 2024 ) + -9415.069 (Jun. 2024 ) + -161.106 (Sep. 2024 ) = NT$-10,020 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bora Pharmaceuticals Co (TPE:6472) Sloan Ratio % Explanation
A former University of Michigan researcher, Richard Sloan's 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones. In fact, for the 40-year period between 1962 and 2001, buying the lowest accrual companies and shorting the highest accrual companies resulted in an average annual compounded return of 18%, more than double the S&P 500's 7.4% annual return over the same period.
If the Sloan Ratio is between -10% and 10%, the company is in the safe zone and there is no funny business with accruals.
If the Sloan Ratio is less than between -25% and -10% on the negative side, and between 10% and 25% on the positive side, this is a warning stage of accrual build up.
If the Sloan Ratio is less than -25% or greater than 25%, and this ratio is consistent over several quarters or even years, be careful. Earnings are highly likely to be made up of accruals.
As of Sep. 2024, Bora Pharmaceuticals Co has a Sloan Ratio of 26.52%, indicating there is a warning stage of accrual build up.
Bora Pharmaceuticals Co Sloan Ratio % Related Terms
Thank you for viewing the detailed overview of Bora Pharmaceuticals Co's Sloan Ratio % provided by GuruFocus.com. Please click on the following links to see related term pages.
Bora Pharmaceuticals Co Ltd is a pharmaceutical company based in Taiwan. It covers the pharmaceutical supply chain from research and development to sales and distribution. The main activities of the Company focus on manufacturing and selling generic, brand, and over-the-counter (OTC) drugs, contract development and manufacturing (CDMO), and developing and selling consumer healthcare products. The Group operates in three reportable segments; Commercial sales segment, Contract Development & Manufacturing Organization segment, and Other segment. The majority of revenue is derived from the Commercial sales segment. Geographically, the company operates in the USA which derives key revenue, Europe, Taiwan, and other regions.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
TPE:6472 has been successfully added to your 